Close this search box.

Lonza expands EU production capacity for Moderna vaccine

Lonza will expand its production capacity of Moderna’s mRNA vaccine mRNA1273 at its manufacturing site in Geelen, the Netherlands. 

The CDMO announced to open a new drug substance production line at Lonza’s site in Geleen, Netherlands, by Q4/2021 to produce up to an additional 300 million doses per year. The new production line in Geleen (NL) will complement Lonza’s existing drug substance production network for COVID-19 Vaccine Moderna.

In May 2020, Lonza and Moderna announced a ten-year strategic collaboration agreement to enable the manufacture of Moderna’s COVID-19 vaccine and additional Moderna products in the future. Since then, Lonza has installed three production lines at its Visp (CH) site and one production line in Portsmouth (US). In April 2021, Lonza and Moderna entered a new agreement to add three further production lines at its Visp (CH) site.

The new production line in Geleen (NL) is expected to be operational by the end of 2021. Lonza will leverage its existing infrastructure in Geleen (NL) to provide fast build-out and ramp-up of operations.